Press Release

NeuroPace Feasibility Study of Its RNS System for Lennox-Gastaut Syndrome Now Underway

First patient receives brain-responsive neuromodulation for LGS, a severe and disabling childhood-onset epilepsy MOUNTAIN VIEW, Calif., November 30, 2022--(BUSINESS WIRE)--NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage…

NeuroPace Inc.November 30, 2022

Press Release

NeuroPace Announces First Patient Implanted in NAUTILUS Pivotal Study for the Treatment of Idiopathic Generalized Epilepsy (IGE)

Groundbreaking NAUTILUS study will evaluate the safety and effectiveness of the RNS System to treat generalized epilepsy in patients aged 12 and older MOUNTAIN VIEW,…

NeuroPace Inc.October 11, 2022

Press Release

NeuroPace Announces First Patient Treated in Pivotal Study Evaluating the RNS System in Adolescents

RESPONSE Study first to evaluate the effectiveness of brain-responsive neuromodulation to treat focal epilepsy in patients 12 through 17 MOUNTAIN VIEW, Calif. — May 4,…

NeuroPace Inc.May 4, 2022

Press Release

NeuroPace Receives IDE Approval to Initiate NAUTILUS Pivotal Study of its RNS System for Idiopathic Generalized Epilepsy

IDE study will be first to evaluate the effectiveness of brain-responsive neuromodulation to treat primary generalized epilepsy in patients aged 12 and older MOUNTAIN VIEW,…

NeuroPace Inc.November 10, 2021

Press Release

NeuroPace Launches nSight Platform and Partnership with Seizure Tracker™ to Provide Doctors With Personalized Information About Their Patients’ Seizure Burden

New Online Physician Portal Integrates RNS System’s EEG Data with Patient Seizure Diary App to Help Doctors Provide More Comprehensive, Data-Driven Care for Epilepsy Patients…

NeuroPace Inc.August 4, 2021

Press Release

NeuroPace Awarded Five-Year NIH Grant Funding of More than $9M to Study RNS System in Patients with Lennox-Gastaut Syndrome

Feasibility IDE study will be the first to evaluate responsive neuromodulation for a severe and disabling childhood-onset epilepsy MOUNTAIN VIEW, Calif. — June 30, 2021…

NeuroPace Inc.June 30, 2021

Press Release

NeuroPace Receives FDA Breakthrough Device Designation for RNS System for Idiopathic Generalized Epilepsy

Company plans to pursue indication expansion to broaden access to include patients with second most common type of epilepsy. MOUNTAIN VIEW, Calif. – March 31,…

RobbyMarch 31, 2021

Press Release

NeuroPace Raises $67 Million Financing to Support Commercial Expansion of the RNS® System for Refractory Epilepsy

Funds will also support clinical trial to pursue new indication for the company’s life-changing neuromodulation technology MOUNTAIN VIEW, Calif. – August 31, 2020 – NeuroPace,…

NeuroPace Inc.August 31, 2020

Press Release

New Published Data Show NeuroPace’s RNS® System Provides Patients with Unprecedented Seizure Reduction and Improved Quality of Life

Personalized, data-driven treatment for refractory focal epilepsy demonstrates unprecedented real-world results and exceptional long-term clinical data MOUNTAIN VIEW, Calif. – July 27, 2020 – NeuroPace,…

NeuroPace Inc.July 29, 2020

Press Release

NeuroPace RNS System Receives FDA Approval for MRI Labeling, Allowing Thousands More Patients to Benefit from Personalized, Data-Driven Epilepsy Treatment

Full-body MRI opens up valuable medical imaging possibilities for RNS System patients MOUNTAIN VIEW, Calif. – March. 9, 2020 – NeuroPace, Inc., a Silicon Valley-based…

NeuroPace Inc.March 6, 2020

Cookie	Duration	Description
cookielawinfo-checbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-advertisement	1 year	Set by the GDPR Cookie Consent plugin, this cookie is used to record the user consent for the cookies in the "Advertisement" category .
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
JSESSIONID	session	The JSESSIONID cookie is used by New Relic to store a session identifier so that New Relic can monitor session counts for an application.
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.

Cookie	Duration	Description
_ga	2 years	The _ga cookie, installed by Google Analytics, calculates visitor, session and campaign data and also keeps track of site usage for the site's analytics report. The cookie stores information anonymously and assigns a randomly generated number to recognize unique visitors.
_gat_UA-55828317-3	1 minute	A variation of the _gat cookie set by Google Analytics and Google Tag Manager to allow website owners to track visitor behaviour and measure site performance. The pattern element in the name contains the unique identity number of the account or website it relates to.
_gid	1 day	Installed by Google Analytics, _gid cookie stores information on how visitors use a website, while also creating an analytics report of the website's performance. Some of the data that are collected include the number of visitors, their source, and the pages they visit anonymously.
CONSENT	2 years	YouTube sets this cookie via embedded youtube-videos and registers anonymous statistical data.
demdex	5 months 27 days	The demdex cookie, set under the domain demdex.net, is used by Adobe Audience Manager to help identify a unique visitor across domains.

Cookie	Duration	Description
_fbp	3 months	This cookie is set by Facebook to display advertisements when either on Facebook or on a digital platform powered by Facebook advertising, after visiting the website.
fr	3 months	Facebook sets this cookie to show relevant advertisements to users by tracking user behaviour across the web, on sites that have Facebook pixel or Facebook social plugin.
VISITOR_INFO1_LIVE	5 months 27 days	A cookie set by YouTube to measure bandwidth that determines whether the user gets the new or old player interface.
YSC	session	YSC cookie is set by Youtube and is used to track the views of embedded videos on Youtube pages.
yt-remote-connected-devices	never	YouTube sets this cookie to store the video preferences of the user using embedded YouTube video.
yt-remote-device-id	never	YouTube sets this cookie to store the video preferences of the user using embedded YouTube video.

Cookie	Duration	Description
AMCV_98CF678254E93B1B0A4C98A5AdobeOrg	2 years	No description
AMCVS_98CF678254E93B1B0A4C98A5AdobeOrg	session	No description
DrupalVisitorMobile	session	No description available.
FASRV	session	No description available.
FORMASSEMBLY	session	No description available.
prism_798681331	1 month	No description

Press Release

Press Release

NeuroPace Feasibility Study of Its RNS System for Lennox-Gastaut Syndrome Now Underway

NeuroPace Announces First Patient Implanted in NAUTILUS Pivotal Study for the Treatment of Idiopathic Generalized Epilepsy (IGE)

NeuroPace Announces First Patient Treated in Pivotal Study Evaluating the RNS System in Adolescents

NeuroPace Receives IDE Approval to Initiate NAUTILUS Pivotal Study of its RNS System for Idiopathic Generalized Epilepsy

NeuroPace Launches nSight Platform and Partnership with Seizure Tracker™ to Provide Doctors With Personalized Information About Their Patients’ Seizure Burden

NeuroPace Awarded Five-Year NIH Grant Funding of More than $9M to Study RNS System in Patients with Lennox-Gastaut Syndrome

NeuroPace Receives FDA Breakthrough Device Designation for RNS System for Idiopathic Generalized Epilepsy

NeuroPace Raises $67 Million Financing to Support Commercial Expansion of the RNS® System for Refractory Epilepsy

New Published Data Show NeuroPace’s RNS® System Provides Patients with Unprecedented Seizure Reduction and Improved Quality of Life

NeuroPace RNS System Receives FDA Approval for MRI Labeling, Allowing Thousands More Patients to Benefit from Personalized, Data-Driven Epilepsy Treatment

PATIENTS

PROVIDERS

CORPORATE

PATIENTS

PROVIDERS

INVESTORS

CORPORATE

Step 1 of 7